Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 5/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6733505 | 0.98 | NAMPT (0.43) | NAMPTCDC7DBF4MAPTKMT2A | |
| SCHEMBL8849171 | 0.87 | MMP8 (0.43) | KMT2AALDH1A1MEN1MMP8 | |
| SCHEMBL280401 | 0.81 | MMP8 (0.56) | KMT2APOLBMEN1MMP8GAA | |
| SCHEMBL6154370 | 0.81 | MMP8 (0.51) | NAMPTCDC7DBF4MAPTKMT2A | |
| SCHEMBL6905840 | 0.81 | MEN1 (0.46) | KMT2AALDH1A1MEN1MMP8GAA | |
| SCHEMBL7264905 | 0.81 | KMT2A (0.46) | NAMPTKMT2APOLBALDH1A1CYP19A1 | |
| SCHEMBL13924228 | 0.80 | GAA (0.48) | MAPTNPSR1ALDH1A1KDM4ECYP19A1 | |
| SCHEMBL3467316 | 0.80 | GAA (0.48) | MAPTNPSR1ALDH1A1KDM4ECYP19A1 | |
| SCHEMBL324361 | 0.80 | KMT2A (0.47) | MAPTKMT2ANPSR1ALDH1A1HPGD | |
| SCHEMBL755729 | 0.80 | CYP19A1 (0.54) | NAMPTCDC7DBF4MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| CN-114728170-B | Compounds active on nuclear receptors | 纽韦卢森公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| EP-4076661-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2022-10-26 | — | — | EP | disclosed |
| CN-114728170-A | Compounds active on nuclear receptors | 纽韦卢森公司 | 2022-07-08 | — | — | CN | disclosed |
| US-9018390-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| US-8642025-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130280211-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-24 | — | — | US | disclosed |
| US-8492553-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2146984-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| EP-0044119-B1 | PROCESS FOR THE PREPARATION OF COPOLYMERS OF ETHYLENE WITH AT LEAST ONE OTHER 1-ALKENE | STAMICARBON B.V. (NL) | 1985-05-29 | — | — | EP | disclosed |
| US-4435552-A | COORDINATION CATALYST CONTAINING HALOACYL COMPOUND | STAMICARBON B.V. (NL) | 1984-03-06 | — | — | US | disclosed |
| EP-0044119-A2 | Process for the preparation of copolymers of ethylene with at least one other 1-alkene | STAMICARBON B.V. (NL) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | NAMPT 764/4885CDC7 2613/4885DBF4 3892/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | NAMPT 764/4885CDC7 2613/4885DBF4 3892/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | NAMPT 764/4885CDC7 2613/4885DBF4 3892/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | NAMPT 4589/4885CDC7 4341/4885DBF4 3823/4885 |
| US-20130280211-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NAMPT 1562/4885CDC7 911/4885DBF4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.